arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Q32 Bio Inc.

QTTB
$8.87 ▼ -0.08 (-0.89%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
69
Health
Good
Bullish
auto_awesome

Analytical Summary

Q32 Bio Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $180.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -6.8% ↗
FCF / Share $-0.15 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↑ +100.0% —
Net Income Profit after all expenses
$-7.61M
↑ +31.0% —
FCF / Share Free cash flow per share
$-0.15
↑ +66.4% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
63
Returns
98
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 39 quarters